Cargando…

Artificial Intelligence Technologies for COVID-19 De Novo Drug Design

The recent covid crisis has provided important lessons for academia and industry regarding digital reorganization. Among the fascinating lessons from these times is the huge potential of data analytics and artificial intelligence. The crisis exponentially accelerated the adoption of analytics and ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Floresta, Giuseppe, Zagni, Chiara, Gentile, Davide, Patamia, Vincenzo, Rescifina, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949797/
https://www.ncbi.nlm.nih.gov/pubmed/35328682
http://dx.doi.org/10.3390/ijms23063261
_version_ 1784674988677136384
author Floresta, Giuseppe
Zagni, Chiara
Gentile, Davide
Patamia, Vincenzo
Rescifina, Antonio
author_facet Floresta, Giuseppe
Zagni, Chiara
Gentile, Davide
Patamia, Vincenzo
Rescifina, Antonio
author_sort Floresta, Giuseppe
collection PubMed
description The recent covid crisis has provided important lessons for academia and industry regarding digital reorganization. Among the fascinating lessons from these times is the huge potential of data analytics and artificial intelligence. The crisis exponentially accelerated the adoption of analytics and artificial intelligence, and this momentum is predicted to continue into the 2020s and beyond. Drug development is a costly and time-consuming business, and only a minority of approved drugs generate returns exceeding the research and development costs. As a result, there is a huge drive to make drug discovery cheaper and faster. With modern algorithms and hardware, it is not too surprising that the new technologies of artificial intelligence and other computational simulation tools can help drug developers. In only two years of covid research, many novel molecules have been designed/identified using artificial intelligence methods with astonishing results in terms of time and effectiveness. This paper reviews the most significant research on artificial intelligence in de novo drug design for COVID-19 pharmaceutical research.
format Online
Article
Text
id pubmed-8949797
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89497972022-03-26 Artificial Intelligence Technologies for COVID-19 De Novo Drug Design Floresta, Giuseppe Zagni, Chiara Gentile, Davide Patamia, Vincenzo Rescifina, Antonio Int J Mol Sci Review The recent covid crisis has provided important lessons for academia and industry regarding digital reorganization. Among the fascinating lessons from these times is the huge potential of data analytics and artificial intelligence. The crisis exponentially accelerated the adoption of analytics and artificial intelligence, and this momentum is predicted to continue into the 2020s and beyond. Drug development is a costly and time-consuming business, and only a minority of approved drugs generate returns exceeding the research and development costs. As a result, there is a huge drive to make drug discovery cheaper and faster. With modern algorithms and hardware, it is not too surprising that the new technologies of artificial intelligence and other computational simulation tools can help drug developers. In only two years of covid research, many novel molecules have been designed/identified using artificial intelligence methods with astonishing results in terms of time and effectiveness. This paper reviews the most significant research on artificial intelligence in de novo drug design for COVID-19 pharmaceutical research. MDPI 2022-03-17 /pmc/articles/PMC8949797/ /pubmed/35328682 http://dx.doi.org/10.3390/ijms23063261 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Floresta, Giuseppe
Zagni, Chiara
Gentile, Davide
Patamia, Vincenzo
Rescifina, Antonio
Artificial Intelligence Technologies for COVID-19 De Novo Drug Design
title Artificial Intelligence Technologies for COVID-19 De Novo Drug Design
title_full Artificial Intelligence Technologies for COVID-19 De Novo Drug Design
title_fullStr Artificial Intelligence Technologies for COVID-19 De Novo Drug Design
title_full_unstemmed Artificial Intelligence Technologies for COVID-19 De Novo Drug Design
title_short Artificial Intelligence Technologies for COVID-19 De Novo Drug Design
title_sort artificial intelligence technologies for covid-19 de novo drug design
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949797/
https://www.ncbi.nlm.nih.gov/pubmed/35328682
http://dx.doi.org/10.3390/ijms23063261
work_keys_str_mv AT florestagiuseppe artificialintelligencetechnologiesforcovid19denovodrugdesign
AT zagnichiara artificialintelligencetechnologiesforcovid19denovodrugdesign
AT gentiledavide artificialintelligencetechnologiesforcovid19denovodrugdesign
AT patamiavincenzo artificialintelligencetechnologiesforcovid19denovodrugdesign
AT rescifinaantonio artificialintelligencetechnologiesforcovid19denovodrugdesign